Funding Received
$25 Million in 1 Round from 1 Investor
Most Recent Funding
$25 Million Series A on September 9, 2010
Headquarters:
Gaithersburg, MD
Description:
Zyngenia is a biotherapeutics company focused on the development of the next-generation of antibody-derived drugs.
Founders:
Peter Kiener
Categories:
Biotechnology
Website:
http://www.zyngenia.com

Company Details

Update

Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybodyâ„¢). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies.

Current Team (2)

Update

Past Team (1)

Update

Funding Rounds (1) - $25M

Update

Board Members and Advisors (3)

Update

Investors (1)

Update

Offices/Locations (1)

Update
  • Office

    21 Firstfield Road

    Suite 200

    Gaithersburg, MD 20878

    USA

Images (1)

Update
  • D65286dc668d815dd1f6cbbfb9aa1fc7